The PI3K p110α inhibitor BYL719 (alpelisib) is currently an approved cancer therapeutic; however, genetic studies in rodents suggest that long-term suppression of insulin/IGF1 signaling mediated PI3K p110α can extend life and healthspan of aged mice. Here, INS is linked to cancer.